---
title: "Recurrent or Progressive IDH1 Mutated Glioma NEO100-01 | Sutter Health"
description: "An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation"
url: "https://www.sutterhealth.org/research/clinical-trials/recurrent-or-progressive-idh1-mutated-glioma-neo100-01-2066909715"
---

1.  [Home](https://www.sutterhealth.org/) /
2.  [Research](https://www.sutterhealth.org/research) /
3.  [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) /
4.  Recurrent or Progressive IDH1 Mutated Glioma NEO100-01

# Recurrent or Progressive IDH1 Mutated Glioma NEO100-01

**Status:** Open to Enrollment

[Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/recurrent-or-progressive-idh1-mutated-glioma-neo100-01-2066909715#enroll)

#### Study details

View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02704858).

#### Locations

-   San Francisco
-   Roseville
-   Palo Alto

#### Clinical trial FAQs

Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs).

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

![Akanksha Sharma, M.D.](https://dyn.mktgcdn.com/p/fx3o4gYSh8A9eZE6O0YXDLIVqIx4iEfnUPC67_kCS-4/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100)

Akanksha Sharma, M.D.

Principal investigator

[View profile](https://www.sutterhealth.org/research/investigators/akanksha-sharma-md-2066909098)

## Sub-Investigators

[Dron Gauchan, M.D.](https://www.sutterhealth.org/research/investigators/dron-gauchan-md-1049681200) , [Roozbeh Mohajer, M.D.](https://www.sutterhealth.org/research/investigators/roozbeh-mohajer-md-2015847331)

## Email us to enroll

-   [Email San Francisco](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Recurrent%20or%20Progressive%20IDH1%20Mutated%20Glioma%20NEO100-01%20in%20San%20Francisco&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.)
-   [Email Roseville](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Recurrent%20or%20Progressive%20IDH1%20Mutated%20Glioma%20NEO100-01%20in%20Roseville&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.)
-   [Email Palo Alto](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Recurrent%20or%20Progressive%20IDH1%20Mutated%20Glioma%20NEO100-01%20in%20Palo%20Alto&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.)

## Related clinical trials

[View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial)

-   Clinical trial
    
    ### [Adjuvant Astrocytomas Grade 3 A072301](https://www.sutterhealth.org/research/clinical-trials/adjuvant-astrocytomas-grade-3-a072301-2082117649)
    
    Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Metastasis Brain NEO212-01](https://www.sutterhealth.org/research/clinical-trials/metastasis-brain-neo212-01-2079170524)
    
    An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Neoadjuvant Glioblastoma GTM-105](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-glioblastoma-gtm-105-2084413544)
    
    Randomized Study of Resection and GammaTile® Followed by Concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM)
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Neoadjuvant Neuroblastoma ANBL2131](https://www.sutterhealth.org/research/clinical-trials/neoadjuvant-neuroblastoma-anbl2131-2022194957)
    
    A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
    
    **Status:** Open to Enrollment
    
-   Clinical trial
    
    ### [Recurrent Glioblastoma SC9-GBM-03](https://www.sutterhealth.org/research/clinical-trials/recurrent-glioblastoma-sc9-gbm-03-2064304836)
    
    A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma.
    
    **Status:** Closed to Enrollment
    

[View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial)

```json
{"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]}
```

```json
{"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/recurrent-or-progressive-idh1-mutated-glioma-neo100-01-2066909715#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Recurrent or Progressive IDH1 Mutated Glioma NEO100-01"}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/recurrent-or-progressive-idh1-mutated-glioma-neo100-01-2066909715#medicalwebpage","name":"Recurrent or Progressive IDH1 Mutated Glioma NEO100-01","description":"An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation","url":"https://www.sutterhealth.org/research/clinical-trials/recurrent-or-progressive-idh1-mutated-glioma-neo100-01-2066909715","inLanguage":"en-US","dateModified":"2026-06-04","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/recurrent-or-progressive-idh1-mutated-glioma-neo100-01-2066909715#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/recurrent-or-progressive-idh1-mutated-glioma-neo100-01-2066909715#breadcrumblist"},"mentions":[{"@type":"Person","name":"Akanksha Sharma, M.D.","url":"https://www.sutterhealth.org/research/investigators/akanksha-sharma-md-2066909098","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/recurrent-or-progressive-idh1-mutated-glioma-neo100-01-2066909715#medicaltrial","name":"Recurrent or Progressive IDH1 Mutated Glioma NEO100-01","alternateName":"An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation","url":"https://www.sutterhealth.org/research/clinical-trials/recurrent-or-progressive-idh1-mutated-glioma-neo100-01-2066909715","description":"An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation","identifier":"NCT02704858","code":{"@type":"MedicalCode","codeValue":"NCT02704858","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT02704858","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Brain Cancer"},{"@type":"MedicalCondition","name":"Glioblastoma"}],"studyLocation":[{"@type":"AdministrativeArea","name":"San Francisco"},{"@type":"AdministrativeArea","name":"Roseville"},{"@type":"AdministrativeArea","name":"Palo Alto"}]}
```
